Keros Therapeutics, Inc. - common stock (KROS) earnings
KROS earnings moved a median of -0.89% by the close. Quarterly and annual KROS reports and results, each read against the price at its own news timestamp. Back to the KROS overview →
21 measured KROS earnings events.
Where these KROS earnings landedvs 21 measured KROS earnings reactions
| Middle 50% of KROS earnings reactions | -4.50% to +1.31% |
|---|---|
| Median reaction (to close) | -0.89% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 KROS earnings events with a measured close landed between -4.50% and +1.31%; 43% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Keros Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +1.28% | +4.91% | |
| Keros Therapeutics Reports Second Quarter 2026 Financial Results | Press release | +1.28% | +4.91% | |
| Form 10-Q Keros Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | -5.28% | -6.39% | |
| Keros Therapeutics Reports Recent First Quarter 2026 Financial Results | Press release | -5.28% | -6.39% | |
| Form 10-K Keros Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.85% | -9.78% | |
| Form 10-Q Keros Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -2.17% | +0.25% | |
| Keros Therapeutics Reports Third Quarter 2025 Financial Results | Press release | -2.17% | +0.25% | |
| Form 10-Q Keros Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | -4.36% | -4.50% | |
| Keros Therapeutics Reports Second Quarter 2025 Financial Results | Press release | -4.36% | -4.50% | |
| Form 10-Q Keros Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | -2.66% | -4.13% | |
| Keros Therapeutics Reports Recent First Quarter 2025 Financial Results | Press release | -2.66% | -4.13% | |
| Form 10-K Keros Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +3.02% | +0.64% | |
| Form 10-Q Keros Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -1.06% | +1.31% | |
| Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results | Press release | -1.06% | +1.31% | |
| Form 10-Q Keros Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -0.89% | |
| Keros Therapeutics Reports Second Quarter 2024 Financial Results | Press release | +0.00% | -0.89% | |
| Form 10-Q Keros Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.97% | +2.97% | |
| Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results | Press release | +0.97% | +2.97% | |
| Form 10-K Keros Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | -0.21% | -6.30% | |
| Form 10-Q Keros Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | +1.32% | -3.00% | |
| Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial Results | Press release | +1.32% | -3.00% |
Keep exploring
More KROS: analyst actions → · SEC filings → · KROS overview →